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Abstract
Background: The current investigation was undertaken to determine key steps differentiating
G:T and G:A repair at the H-ras oncogenic hot spot within the nuclear environment because of the
large difference in repair efficiency of these two mismatches.
Results: Electrophoretic mobility shift (gel shift) experiments demonstrate that DNA containing
mismatched bases are recognized and bound equally efficiently by hMutSα  in both MMR proficient
and MMR deficient (hMLH1-/-) nuclear extracts. Competition experiments demonstrate that while
hMutSα  predictably binds the G:T mismatch to a much greater extent than G:A, hMutSα
demonstrates a surprisingly equal ratio of competitive inhibition for both G:T and G:A mismatch
binding reactions at the H-ras hot spot of mutation. Further, mismatch repair assays reveal almost
2-fold higher efficiency of overall G:A repair (5'-nick directed correct MMR to G:C and incorrect
repair to T:A), as compared to G:T overall repair. Conversely, correct MMR of G:T →  G:C is
significantly higher (96%) than that of G:A →  G:C (60%).
Conclusion:  Combined, these results suggest that initiation of correct  MMR requires the
contribution of two separate steps; initial recognition by hMutSα  followed by subsequent binding.
The 'avidity' of the binding step determines the extent of MMR pathway activation, or the activation
of a different cellular pathway. Thus, initial recognition by hMutSα  in combination with subsequent
decreased binding to the G:A mismatch (as compared to G:T) may contribute to the observed
increased frequency of incorrect repair of G:A, resulting in the predominant GGC →  GTC (Gly
→  Val) ras-activating mutation found in a high percentage of human tumors.
Background
Several different DNA repair systems have evolved within
all living cells to correct mispaired or damaged nucleotide
residues generated either by endogenous events or by
exposure to exogenous mutagenic agents [1,2]. The fre-
quency of mutational events varies widely within the
genome, and specific sites harboring increased frequency
of mutation are now defined as 'hot spots' of mutation.
The human ras protooncogene family contains three such
hot spots – codons 12, 13, and 61. Factors contributing to
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these and other hot spots of mutation are still largely
unknown, despite much investigation, but now appear to
have several different contributions, such as type of DNA
damage, genomic location, surrounding sequence, cell
cycle position, efficiency of the optimal DNA repair path-
way, and involvement of alternate repair and other cellu-
lar pathways.
DNA mismatch repair (MMR) is a repair system that cor-
rects mispaired nucleotides and insertion/deletion loops
(IDLs), resulting from replication, recombination, or
repair errors. Consequences of defects in this DNA repair
pathway are evidenced by microsatellite instability (MSI),
elevated mutation frequency throughout the genome,
enhanced recombination events, as well as tolerance to
cytotoxic effects of alkylating agents as evidenced by
decreased apoptosis. Deficient MMR is, in turn, associated
with hereditary nonpolyposis colorectal cancer (HNPCC),
as well as other types of sporadic tumors in humans and
animal models [3-6]. Although the contribution of MMR
to highly mutable genomic sites other than microsatellite
sequences is largely unknown, several specific genetic
mutations involved in neoplastic progression, including
ras-activating mutations, have been reported as frequent
occurrences in HNPCC and other MSI tumors [7,8].
DNA MMR is conserved amongst highly divergent species,
reflecting the essential role of this DNA repair process
[9,10]. The MMR system in eukaryotes is more complex
and has different mismatch-specific repair efficiencies
than that of E. coli [11-13]. Several human homologs of
bacterial MutS and MutL proteins have now been identi-
fied [14-19]. The primary human homologs for MutS that
play instrumental roles in MMR include hMSH2, hMSH6,
and hMSH3 [20,21]. The hMutSα  heterodimer (hMSH2
and hMSH6) has been demonstrated to recognize and
bind DNA mispairs and short IDLs [14,21-24]. The
hMutSβ  heterodimer (hMSH2 and hMSH3) preferentially
recognizes and binds IDLs of up to 12 nucleotides.
Human cells lacking hMSH2 protein expression also lack
its cognate partners, hMSH3 and hMSH6 (due to
decreased stability). This lack is associated with defective
MMR, microsatellite instability, and is associated with a
high percentage of HNPCC [25]. MutL homologs that are
most relevant to human MMR are hMLH1 and hPMS2,
which form the hMutLα  heterodimer [9,26]. Similar to
the observed instability of individual MutS homologs,
lack of hMLH1 protein expression results in the lack of
hPMS2 protein, which in turn results in microsatellite
instability, defective MMR, and is also associated with a
high percentage of HNPCC [9,10,15,25,27-32]. The
MutLα  heterodimer is thought to act as a molecular
matchmaker between the MutSα -DNA complex and
downstream enzyme activities responsible for subsequent
identification, excision, and replacement of the incorrect
base [9,19]. Biochemical interactions and genetic studies
have further implicated proliferating cell nuclear antigen
(PCNA), exonuclease I (EXO1), replication protein A
(RPA), replication factor C (RFC), and DNA polymerase δ
as active participants in the MMR pathway
[19,27,29,30,33-35]. Recently, the differential require-
ment of specific proteins associated with MMR have been
identified for both 3'-nick directed and 5'-nick directed
MMR by the use of an in vitro model [35,36].
We have previously demonstrated that the efficiency of
correct mismatch repair within the cell can differ signifi-
cantly, depending on exact type of mismatch, site-specific
location, phase of cell cycle, or cell type [23,24,37,38].
Within this report, we have focused on a more precise
understanding of the differences between MMR protein
interactions with a G:A (least repaired) or G:T (best
repaired) mismatch located at H-ras codon 12 to better
understand molecular events leading to activating muta-
tions at this site. Our current results indicate that initial
recognition and subsequent binding for repair signaling
by hMutSα  may be two separably measurable steps in the
MMR pathway that can significantly affect downstream
cellular events.
Results
Specificity of hMutSα  protein binding to DNA mismatches 
at H-ras codon 12
To determine that the binding complex recognizing mis-
matches at codon 12 of H-ras in HCT116 + Ch.3 nuclear
extract is composed of hMutsα , DNA binding reactions
were conducted using [32P]-G:T oligos incubated with
nuclear extracts from these MMR proficient cells. In con-
firmation of hMutSα  binding to a G:T mismatch at this
oncogenic site, the hMutSα  :DNA complex was efficiently
interrupted by goat anti-hMSH6 and with rabbit anti-
hMSH2 (Figure 1, lanes 3 and 5), but not by BSA, nonspe-
cific goat IgG, or nonspecific rabbit IgG (lanes 1, 2, and 4,
respectively). As further evidence of specific hMutsα :DNA
mismatch binding, addition of 1.5 mM ATP completely
disrupted the gel shifted band (results not shown)
[24,30]. Thus, MMR protein binding to a G:T mismatch
located at H-ras codon 12 within the nuclear environment
appears to be primarily, if not exclusively, hMutSα .
Comparison of hMutSα  binding 'avidity' to a G:T mismatch 
located at H-ras codon 12 within MMR competent and 
deficient nuclear extracts
The HCT116 cell line completely lacks both 3' and 5' nick-
directed MMR, putatively due to lack of hMLH1 expres-
sion, although these cells normally express hMSH2 and
hMSH6. To determine if hMutSα  recognition and binding
of a mismatch at the H-ras  codon 12 hot spot might
undergo alteration within HCT116 cells, in conjunction
with the lack of hMutLα , binding competitionBMC Molecular Biology 2005, 6:6 http://www.biomedcentral.com/1471-2199/6/6
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experiments were performed. Figure 2 is a comparison of
the amount, or 'avidity', of hMutSα  binding affinity
within MMR proficient (HCT116 + Ch. 3) and within
MMR deficient (HCT116) nuclear extracts. These gel shifts
demonstrate virtually identical mismatch specific binding
avidity of hMutSα  to [32P]-G:T-oligo. As well, 50X molar
excess of unlabeled G:T-oligo, which does not completely
inhibit hMutSα  gel shift of the radioactively labeled mis-
match, demonstrates a similar degree of competitive inhi-
bition of mismatch specific binding in both MMR
proficient and MMR deficient nuclear extracts (Fig. 2,
lanes 3 and 5). These results provide strong evidence that
there is no discernable difference in hMutSα  binding avid-
ity to a G:T mismatch at H-ras  codon 12, despite that
HCT116 + Ch. 3 is MMR proficient and HCT116 lacks
expression of hMutLα  and is MMR deficient.
Comparison of competitive inhibition of hMutSα  binding 
avidity to G:T versus G:A mispairs at H-ras codon 12
We have previously determined that the G:A mismatch at
H-ras codon 12 is accurately repaired back to G:C much
less frequently than G:T [37]. In addition, we have previ-
ously demonstrated that recognition and binding of this
poorly repaired mismatch is also very weak within HeLa
nuclear extracts [23]. We therefore asked if competitive
Specific interaction of hMSH6 and hMSH2 with site-specific  mismatched DNA at H-ras codon 12 Figure 1
Specific interaction of hMSH6 and hMSH2 with site-specific mis-
matched DNA at H-ras codon 12. Protein-DNA binding reac-
tions and gel shifts were performed using nuclear extracts 
from HCT 116 + Ch. 3 and equal cpm of [32P]-G:T-oligo (69-
mer) in the presence of 100X molar excess of cold (unla-
beled) homoduplex (G:C). BSA, goat-, or rabbit-nonspecific 
IgG (lanes 1, 2, 4 respectively), goat anti-hMSH6 (lane 3), and 
rabbit anti-hMSH2 (lane 5) were also included in the binding 
reactions as indicated. The lower gel shift band in each lane is 
due to biotin end-labeling of the probe.
Comparison of binding avidity of G:T-containing oligomer by  MMR proficient (HCT 116 + Ch. 3) and MMR deficient (HCT  116; hMLH1-/-) nuclear extracts Figure 2
Comparison of binding avidity of G:T-containing oligomer by MMR 
proficient (HCT 116 + Ch. 3) and MMR deficient (HCT 116; 
hMLH1-/-) nuclear extracts. Equal aliquots of nuclear extracts 
from HCT 116 + Ch. 3 (lanes 1–3) or HCT 116 (lanes 4–5) 
were incubated with equal cpm of [32P]-G:T-oligo (69-mer) 
and 50X molar excess cold (unlabeled) oligo as indicated.BMC Molecular Biology 2005, 6:6 http://www.biomedcentral.com/1471-2199/6/6
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inhibition by several different concentrations of these
mismatches would reveal more specific mechanisms of
these intriguing differences at this same location. Firstly,
using increasing concentrations of unlabeled G:T oligo as
a competitor for [32P]-G:T-oligo, we observe the expected
highly competitive inhibition of the radioactive G:T mis-
match gel shift band in the presence of as little as 25X cold
G:T-oligo (Figure 3a; compare cold G:T fold increase lanes
"0" up through "100"). In comparison, the radioactive
G:T-oligo gel shift band is much less competitively inhib-
ited by increasing concentrations of cold G:A oligo (Figure
3a; compare cold G:A fold increase lanes "0" up through
"100"), further confirming the observed preference of
hMutSα  for a G:T mismatch as compared to a G:A mis-
match at the H-ras codon 12 hot spot of mutation. Com-
parison of the densitometric band intensities reveal that
even 25X cold G:T oligo can successfully decrease hMutSα
binding to radioactive G:T by 80%, but that 25X cold G:A
decreases hMutSα  binding to radioactive G:T by only
10%.
An alternate approach to more precisely define the extent
of this phenomenon was to measure competitive inhibi-
tion of radioactively labeled G:A-oligo (rather than of the
avidly bound [32P]-G:T-oligo) by incubation with unla-
beled G:A-oligo, to determine if equal ratios of competi-
tive binding might occur for G:T and G:A, despite the very
different avidities of hMutSα  for each mismatch. This
would provide an indication of equal recognition of each
type of mismatch by hMutSα , despite unequal binding
avidity for these two mismatches. For these experiments,
it was necessary to extend incubation periods from 30
min. to 2.5 hr, as sufficient concentrations of gel shifted
bands can be detected with the G:A oligo only after
extended incubation (unpublished observations). As
expected, binding of hMutSα  to [32P]-G:A-oligo is approx-
imately 100 fold weaker in intensity than for [32P]-G:T-
oligo after the extended incubation (Figure 3b; compare
"Intensity" of lanes 1 and 3 on densitometric graph).
However, 100X molar excess of cold G:A-oligo competi-
tively inhibits MMR protein binding to [32P]-G:A-oligo by
89%, which is similar to the same concentration of cold
G:T-oligo competitive inhibition of MMR protein binding
to [32P]-G:T-oligo (97%), as determined by comparison of
the densitometric intensity of each band. All of the above
experiments have been repeated with similar results.
MMR at H-ras codon 12 hot spot of mutation
Table 1 contains the results of a MMR assay designed to
score nick-directed MMR as correct, incorrect or
unrepaired [39]. Positive control experiments demon-
strate that MMR at the H-ras codon 12 sequence within
the pUC19 vector is nick-directed, yielding a high degree
of correct repair by MMR proficient E. coli (DH5α ); G:T →
G:C = 95%, G:A →  G:C = 78%, in agreement with our pre-
viously published results using a different plasmid vector
[23]. Additionally, inserting the same H-ras 69 mer into a
pUC18 vector to determine effects of reverse orientation
of the oligo and 'nicked' strand resulted in an almost iden-
tical frequency of correct repair at codon 12; G:T →  G:C =
100%, G:A →  G:C = 78%. These results confirm that the
mismatch is recognized and repaired by nick-directed bac-
terial MMR and that there is no strand bias for MMR dur-
ing high copy number bacterial replication of this
plasmid. Background repair after direct transformation
into NR9161 E. coli (MMR deficient) was consistently
between 41–44% for both mismatches (data not shown),
and is favorably comparable to an average of 50 – 60%
background repair efficiency by this and other strains of
MMR deficient E. coli (personal communication with Roel
Schaaper).
Results within Table 1 were determined by incubating
plasmids containing a G:T or G:A mismatch at the H-ras
codon 12 middle base pair location containing a 5' nick
on the "T" or "A" strand (as described in methods) with
MMR proficient (HCT116 + Ch. 3) or MMR deficient
(HCT116) nuclear extracts. Efficiency of correct, incorrect,
and total (correct + incorrect) MMR for each mismatch
was subsequently calculated (as described in methods)
[39]. Surprisingly, total repair of the G:A mismatch (30%;
G:A →  G:C + T:A) was almost twice as high as for G:T
(18.2%; G:T →  G:C + A:T). This phenomenon was consist-
ently observed within the several different experiments
required to obtain the total results depicted in Table 1,
and was statistically significant (p < 0.05). In direct con-
trast, correct (nick-directed) repair of G:A →  G:C (60%)
was significantly low when compared to correct  (nick-
directed) repair of G:T →  G:C (96%) (p < 0.005). Inad-
vertent nicks in the "G" (correct) strand of the H-ras 69
mer or pUC plasmid during preparation could not have
contributed to the increased total, or increased incorrect
repair (G:A →  T:A) results for the G:A mismatch because
the efficiency of incorrect repair would then be similar for
both the G:T and the G:A mismatch. Instead, MMR results
within Table 1 were found to be consistently different for
the two mismatches, and are the compiled results of sev-
eral different mismatch-containing plasmid preparations
and subsequent MMR assays. In addition, MMR proficient
E. coli nick-directed repair results are consistently high, for
both mismatch-containing plasmid preparation subse-
quently used for each nuclear extract MMR assay (data not
shown). As well, MMR deficient E. coli repair ratios (cor-
rect to incorrect) are 1:1 after transformation of unmeth-
ylated plasmids (prepared by replication in GM2929; E.
coli dam-dcm-). In combination, all of the above control
experiments demonstrate a lack of any significant unin-
tentional misrepair events on either strand of DNA, for
either site-specific mismatch plasmid preparation. There-
fore, the results within Table 1 suggest that increased totalBMC Molecular Biology 2005, 6:6 http://www.biomedcentral.com/1471-2199/6/6
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Binding avidity of hMutSα  to G:T versus G:A at H-ras codon 12 Figure 3
Binding avidity of hMutSα  to G:T versus G:A at H-ras codon 12 (a) Equal cpm of [32P]-G:T-oligo (69 mer) were incubated with equal 
concentrations of nuclear extract (HCT116 + Ch. 3) in the presence of increasing concentrations of unlabeled (cold) G:T- or 
G:A-containing oligo, and 100X cold G:C oligo. (b) Equal aliquots of nuclear extract were incubated for 2.5 hours (versus 30 
minutes) with equal cpm of each [32P]-G:T- or [32P]-G:A-oligo alone (lanes 1 and 3), or also with respective 100X molar excess 
cold G:T or G:A oligo (lanes 2 and 4). Bar graphs are densitometry results of corresponding radioactive band intensities.BMC Molecular Biology 2005, 6:6 http://www.biomedcentral.com/1471-2199/6/6
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repair (correct + incorrect) combined with increased
incorrect repair of G:A, as compared to the decreased total
repair and increased correct MMR repair of G:T, may result
in increased mutational events when a G:A mismatch
occurs at this oncogenic site. Somewhat surprisingly,
MMR deficient nuclear extracts did not repair either mis-
match at codon 12 above background, indicating a com-
plete lack of alternate DNA repair activity that can correct
either mismatch at this oncogenic site. Therefore these
results indicate that the observed repair efficiencies in
MMR proficient nuclear extracts are due solely to MMR
activity, rather than to a combination of MMR and other
DNA repair pathways. Alternatively, it is possible that the
methods used for nuclear extract preparation or the in
vitro MMR assay might cause an artifactual decrease in the
activity of other DNA repair pathways.
Discussion and conclusions
Previous investigations of ours have revealed significantly
decreased nick-directed G:A →  G:C repair at codon 12 of
H-ras, as compared to G:T →  G:C repair at this location
[23,37]. Decreased MMR of G:A has also been observed
within different sequences by other investigators,
although molecular mechanisms for these differences
remain obscure [12]. The current investigation was under-
taken to determine key steps differentiating G:T and G:A
repair pathways at the H-ras oncogenic hot spot within the
nuclear environment. Our results suggest that, firstly, the
MMR pathway is the primary, if not the only, DNA repair
pathway that can recognize and is subsequently responsi-
ble for the repair of both mismatches at this oncogenic
location within the cell. Secondly, although 'recognition'
of either G:T or G:A by hMutSα  is likely equal, and is
essential for initiation of MMR, the avidity – or strength –
of hMutSα  binding to either mismatch is not equal, and
may play a significant role in the decision of whether to
activate nick-directed correct MMR, or the activation of an
alternate response pathway. In support of this concept,
and in correlation with weak hMutSα  binding to G:A, we
have observed significantly decreased nick-directed (cor-
rect) MMR of G:A →  G:C (60%), as compared to nick-
directed MMR of G:T →  G:C (96%). We have however,
consistently measured almost twice the efficiency of total
repair of G:A (to either G:C or T:A) as compared to total
G:T repair (to G:C or A:T) at this oncogenic site. This phe-
nomenon appears to be due to increased non nick-
directed incorrect repair of G:A →  T:A (rather than to rep-
lication without repair, which results in a mixture of G:C
and T:A).
This raises the possibility that (a) initial recognition of a
mismatch is essential but separable from (b) differential
binding of MMR proteins to specific mismatches, which
in turn is directly correlated either with nick-directed cor-
rect  MMR, or with alternate events other than nick-
directed MMR. In support of this concept, Wang, et. al. has
recently demonstrated by atomic force microscopy that E.
coli  MutS-DNA complexes exist in two conformations
[40]. The initial recognition of a mismatch by MutS results
in a localized kink in the DNA conformation and is
termed the initial recognition complex (IRC). The second
step is required for MMR and is a further conformational
change in which the localized kink in the DNA becomes
unbent. This is called the ultimate recognition complex
Table 1: Mismatch repair at an oncogenic site within MMR proficient and MMR deficient human nuclear extracts.
HCT 116 + Ch. 3; H-ras codon 12 middle G:C HCT 116; H-ras codon 12 middle G:C
G:T G:A G:T G:A
*Total repaira (correct & incorrect) 18.2 % 30 % ∅ b ∅
**Correct repaira (% of total) (96%) (60%) ∅∅
**Incorrect repaira (% of total) (4%) (40%) ∅∅
Total # analyzed 99 100 78 91
a Repair efficiency above background for each mismatch at H-ras codon 12 by each human nuclear extract was determined by the following 
equations [39].
Total repair efficiency= 100 × (1 - [fraction of nonrepaired mixture incubated with human nuclear extract results / fraction of nonrepaired results 
of direct transformation of NR9161]).
Correct repair efficiency= 100 × {(fraction of correctly repaired incubated with human nuclear extract) - [(fraction of correct repair by NR9161 
direct transformation) × (1 - fraction of total repair efficiency)]}.
Incorrect repair efficiency= Total repair efficiency - Correct repair efficiency.
b No repair detected above background.
* Designates statistical difference between HCT116 + Ch.3 G:T and G:A repair at P < 0.05.
**Designates statistical difference between HCT116 + Ch.3 G:T and G:A repair at P < 0.005.BMC Molecular Biology 2005, 6:6 http://www.biomedcentral.com/1471-2199/6/6
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(URC) and may be the conformation required for ATP
activation and subsequent MMR activity. It is also possible
that either differential binding kinetics (not measurable
by gel shift), or very low avidity of binding or a different
molecular binding mechanism (undetectable by gel shift)
may contribute to subsequent cellular events specific to
the G:A mismatch. These possibilities are currently being
investigated. An additional hypothesis has been proposed
by Junop, et. al., placing E. coli MutS in the role of 'author-
izing' different repair events [41]. Also, it is now well doc-
umented that while hMutSα  recognizes DNA damage
other than mismatches, the MMR pathway does not
appear to play a direct role in the repair of these damaged
bases, but rather is associated with initiation of cell cycle
and/or apoptotic events and therefore is described as a
"sensor of genetic damage" within this context. The
molecular mechanisms contributing to the various cellu-
lar activities associated with the well documented hMutSα
recognition and differential binding to different DNA
structures is not yet clear. Although there does not appear
to be a consistent physical size or shape of hMutSα
recognizable structures that trigger different pathways of
cellular activity, DNA sequence context does appear to
play a role [9,12].
Figure 4 is the model summarizing our hypothesis. This
concept is compatible with our current set of experimental
data, and with the recently described two-step conforma-
tional alteration of the E. coli MutS-DNA recognition com-
plex [40]. Briefly, hMutSα  appears to equally recognize
both G:T and G:A mismatches at the codon 12 hot spot of
mutation, but binds more avidly to G:T, or the "URC"
conformation. The stronger, or alternate conformational,
binding of hMutSα  to G:T results in increased accuracy of
MMR, but may decrease overall repair efficiency. The less
avidly bound G:A mismatch, or the "IRC" conformation,
is repaired with increased total efficiency as compared to
G:T, but accuracy is sacrificed.
These results agree with, and build upon our previous
experimental results, and also agree with the presence of
specific mutations predominantly found in human
tumors [23,24,37]. It has now been demonstrated by sev-
eral different investigators that, although any base pair
other than G:C at the H-ras codon 12 location is activat-
ing, the majority of human tumors containing mutations
at this site are G:C →  T:A transversions [42-44]. Our
observed increased overall MMR of G:A, combined with a
high ratio of incorrect MMR of G:A →  T:A at this oncogenic
location correlates well with the predominant GGC →
GTC (Gly →  Val) ras-activating mutation found in a high
percentage of human tumors [42,44,45]. Thus the dem-
onstration of a significant increase in the frequency of
both total repair and incorrect repair of the G:A mismatch
at the H-ras codon 12 oncogenic hot spot of mutation,
combined with a complete lack of rescue by other DNA
repair pathways, is biologically relevant.
Methods
Nuclear extracts, oligonucleotides, and site-specific 
mismatched plasmids
Human colorectal carcinoma cell lines HCT116 and
HCT116 + Ch. 3 were cultured in Iscove's Modified Dul-
becco's Medium supplemented with 10% fetal bovine
serum (FBS) at 37°C, 5% CO2. HCT116 + Ch. 3 cell line
also received 0.4 mg/ml Geneticin (G418). Both HCT cell
lines were kind gifts of C. Richard Boland; UCSD. Nuclear
extracts were prepared as described previously [46]. Syn-
thetic oligonucleotides of 69 bases containing the coding
strand sequence 5'-AATTCACGGAATATAAGCTGGTGGT-
GGTGGGCGCCGGCG GTTGGGCAAGAGTGCGCTGAC-
CATCCAGG-3', as well as complementary noncoding
oligomers, were obtained from Operon (Alameda, CA).
The above 69 mer oligo is a portion of the coding
sequence of human H-ras DNA. The bolded underlined
Grepresents H-ras codon 12 middle G position, plus an
additional 30 bases of H-ras sequence both 5' and 3' of
codon 12, with an Eco R1 site 5' and a Bam H1 site 3'
(restriction enzyme recognition nucleotides in italics).
The wild type sequence (coding strand containing codon
12 middle G) was 5'-phosphorylated. Mismatch contain-
ing noncoding strand sequences (either T or A opposite
codon 12 middle base G) were not phosphorylated, thus
providing a 5' nick in the strand containing the incorrect
base after ligation into the pUC19 plasmid. All other rea-
gents were purchased from Sigma unless otherwise noted.
Preparation of site-specific mismatched oligonucleotides 
and plasmids
Complementary 69 mer oligos containing the wild type
sequence at codon 12; middle base (coding strand G) and
one mismatched base (noncoding strand T or A), as
described above, were annealed in an equimolar ratio at a
final concentration of 0.2 µg DNA per µl of annealing
buffer (1 mM Tris-HCL, 1 mM MgCl2, pH 7.5). Ligation of
annealed mismatched oligos to Eco R1/Bam H1 digested
pUC19 DNA was accomplished at a 20:1 molar ratio of 69
mer to pUC19 DNA (~3–6 ng DNA per µl of ligation solu-
tion), using T4 ligase, per manufacturer's recommenda-
tions (Invitrogen Corp.; Carlsbad, CA). The pUC19 vector
used for ligation of mismatch-containing H-ras oligo for
subsequent measurement of MMR within nuclear extracts
was grown in GM2929 (E. coli dam-dcm-). The pUC19 and
pUC18 plasmids used as positive controls for correct bac-
terial mismatch repair were grown in DH5α  (E. coli dam+).
Electrophoretic gel mobility shift assays
Gel shift assays were performed using nuclear extracts
from either HCT116 or HCT116 + Ch. 3 cells and [32P]-
dATP-labeled-69 mer duplexes by a fill-in reaction, usingBMC Molecular Biology 2005, 6:6 http://www.biomedcentral.com/1471-2199/6/6
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[α -32P]-dATP and Klenow polymerase, per manufacturer's
protocol (Invitrogen). Each nuclear protein-DNA binding
assay was performed using 0.8 – 1.0 × 105 cpm homodu-
plex or heteroduplex 69 mer and 5–10 µg protein from
nuclear extract solution in an equal volume of 2X gel shift
reaction buffer, resulting in a final concentration of 1 mM
MgCl2, 0.5 mM EDTA, 0.5 mM DTT, 50 mM NaCl, 10 mM
Tris-HCL, pH 7.5, 0.1 mg/ml poly [dI:dC], 5 mg/ml BSA,
6% glycerol, in a final volume of 15 – 20 µl. In addition,
each reaction contained 100-fold molar excess (100X)
unlabeled homoduplex 69 mer, unless otherwise noted.
Incubations were for 30 min. at 37°C, unless otherwise
noted. Gel shifts of each reaction were electrophoresed at
20 mA within a 4.8% nondenaturing acrylamide gel in 0.5
× TBE buffer, at room temperature. Radioactively labeled
oligomers were visualized by autoradiography of the
dried gel.
Site-specific mismatch repair assay within human nuclear 
extracts
An in vitro mismatch repair assay was performed essen-
tially as described by Thomas et. al. [39], except for mod-
ifications as described below. For each reaction, 14 fmols
of pUC19 plasmid containing site-specific mismatched H-
ras 69 mer, with a nick on the same strand and 36 bases 5'
of the incorrect base, was incubated with 50 µg of
Repair model of hMutSα  MMR Figure 4
Repair model of hMutSα  MMR. Model of hMutSα  initial recognition (equal) of G:T and G:A, followed by repair (differential) of 
DNA containing a G:T or a G:A mismatch at the H-ras codon 12 location. hMutSα  recognizes and forms an initial recognition 
complex (IRC) with both mismatches equally, and then binds more strongly to G:T, perhaps by undergoing an additional con-
formational step to the ultimate recognition complex (URC), which does not occur with G:A [40]. This results in more accu-
rate repair of G:T, but more frequent total repair of G:A. See text for further discussion.BMC Molecular Biology 2005, 6:6 http://www.biomedcentral.com/1471-2199/6/6
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HCT116 + Ch. 3 or HCT116 nuclear extract in a final vol-
ume of 25 µl containing 30 mM HEPES buffer, pH 7.9,
100 µM each of dATP, dCTP, dGTP and dTTP, 200 µM
each of CTP, GTP and UTP, 4 mM ATP, 40 mM creatine
phosphate, 100 ng/µl creatine phosphokinase, 0.5 mM
DTT, and 7 mM MgCl2. Negative control experiments
were performed in the above solution without nuclear
extract. Each reaction was incubated at 37°C for one hour,
as described [39]. Plasmid DNA containing the H-ras
insert was recovered using Wizard SV Miniprep System per
manufacturer's directions (Promega; Madison, WI), and
subsequently used to transform E.coli  strain NR9161
(MutL-). In addition, DH5α  (MMR proficient E. coli) were
transformed directly with the ligated and nicked plasmid
as a positive control for correct mismatch repair [37]. Sub-
sequently, plasmid DNA was purified from ampicillin-
resistant bacterial colonies and digested with Nae I, which
recognizes a single restriction digestion site unique to the
wild type H-ras sequence at codon 12 middle base pair
(G:C) [23]. After electrophoresis in 1% agarose, banding
patterns of resulting DNA fragments were analyzed to
score plasmids as having correct, incorrect, or no repair
[23,37,38].
MMR efficiency of each human nuclear extract assay,
above MMR deficient bacterial background repair, was
determined by the following equations [39]:
Total repair efficiency = 100 × (1 - [fraction of unrepaired
plasmids incubated with human nuclear extract results /
fraction of unrepaired untreated plasmids from direct
transformation of NR9161]).
Correct repair efficiency = 100 × {(fraction of correctly
repaired incubated with human nuclear extract) - [(frac-
tion of correct repair by NR9161 direct transformation) ×
(1 - fraction of total repair efficiency)]}.
Incorrect repair efficiency = Total repair efficiency - Cor-
rect repair efficiency.
Statistical comparisons of G:T and G:A results were con-
ducted by a non-parametric equivalent to the Student's t-
test for differences between proportions. Statistical
significance was indicated for those comparisons with a P
< 0.05 assuming a 2-tailed distribution [47].
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